Expanding the scope of novel 1,2,3-triazole derivatives as new antiparasitic drug candidates.

We have previously shown that prenyl and aliphatic triazoles are interesting motifs to prepare new chemical entities for antiparasitic and antituberculosis drug development. In this opportunity a new series of prenyl-1,2,3-triazoles were prepared from isoprenyl azides and different alkynes looking for new antimalarial drug candidates. The compounds were prepared by copper(i) catalyzed dipolar cycloaddition of the isoprenyl azide equilibrium mixture providing exclusively 1,4-disubstituted 1,2,3-triazoles in a regiospecific fashion. The complete collection of 64 compounds was tested on chloroquine-sensitive (CQ sensitive), Sierra Leone (D6), and the chloroquine-resistant, Indochina (W2), strains of and those compounds which were not previously reported were also tested against , the causative agent for visceral leishmaniasis. Thirteen analogs displayed antimalarial activity with IC below 10 μM, while the antileishmanial activity of the newly reported analogs could not improve upon those previously reported. Compounds 1o and 1r were identified as the most promising antimalarial drug leads with IC below 3.0 μM for both CQ-sensitive and resistant strains with high selectivity index. Finally, a chemoinformatic analysis was performed to evaluate physicochemical parameters, cytotoxicity risk and drug score. The validation of a bifunctional farnesyl/geranylgeranyl diphosphate synthase FPPS/GGPPS as the potential target of the antimalarial activity of selected analogs should be further investigated.